Literature DB >> 12553355

Volume and impact of second-opinion consultations by radiologists at a tertiary care cancer center: data.

Pamela J DiPiro1, Eric vanSonnenberg, Sabah S Tumeh, Pablo R Ros.   

Abstract

RATIONALE AND
OBJECTIVES: Patients with cancer who are referred to a dedicated oncology center usually have undergone previous imaging studies that the oncologists typically desire to have reviewed by radiologists. Such reinterpretations can be complex and time-consuming, yet many institutions do not systematically account for them as part of the total workload. The purpose of this study was to ascertain the numbers and types of second-opinion consultations performed by radiologists at a tertiary care cancer center, and to assess their effect on work volume.
MATERIALS AND METHODS: A survey of referring clinicians was undertaken to evaluate the numbers and types of second-opinion consultations requested of radiologists at the Dana Farber Cancer Institute during a 12-month period. Consultations included review of studies from outside institutions, and cases from Dana Farber in which further comparison was needed. The number of consultations requiring additional tumor size measurements was tallied. The mean daily number of new studies interpreted by radiologists was used as a benchmark of work volume.
RESULTS: Radiologists performed 4,664 consultations during 254 workdays, interpreting a mean of 18 additional studies (range, 4-42) per day as a result of referrals for second opinion. These included 3,638 (78%) cross-sectional studies (ie, computed tomographic [CT], magnetic resonance [MR], and ultrasound [US] studies), 674 (14%) mammograms, 220 (5%) plain radiographs, 132 (3%) nuclear medicine scans, and one galactogram. Of the 4,664 consultations, 1,306 (28%) were performed to obtain tumor measurements, many of these involving five to 10 bidimensional calculations per study. A mean of 101 new examinations per day was performed by radiologists during the same 12-month period, including cross-sectional studies (CT and US scans) (56%), plain radiographs (34%), and mammograms (11%). MR imaging was not performed.
CONCLUSION: Second-opinion consultations increased the average daily work volume by 18%. This has implications for workforce, as well as for compensation in terms of relative value units and finances for this previously unquantified service.

Entities:  

Mesh:

Year:  2002        PMID: 12553355     DOI: 10.1016/s1076-6332(03)80671-2

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  5 in total

1.  Do long radiology workdays affect nodule detection in dynamic CT interpretation?

Authors:  Elizabeth A Krupinski; Kevin S Berbaum; Robert T Caldwell; Kevin M Schartz; Mark T Madsen; David J Kramer
Journal:  J Am Coll Radiol       Date:  2012-03       Impact factor: 5.532

2.  Long radiology workdays reduce detection and accommodation accuracy.

Authors:  Elizabeth A Krupinski; Kevin S Berbaum; Robert T Caldwell; Kevin M Schartz; John Kim
Journal:  J Am Coll Radiol       Date:  2010-09       Impact factor: 5.532

3.  Second opinions in orthopedic oncology imaging: can fellowship training reduce clinically significant discrepancies?

Authors:  Aleksandr Rozenberg; Barry E Kenneally; John A Abraham; Kristin Strogus; Johannes B Roedl; William B Morrison; Adam C Zoga
Journal:  Skeletal Radiol       Date:  2018-07-12       Impact factor: 2.199

Review 4.  Radiology Consultation in the Era of Precision Oncology: A Review of Consultation Models and Services in the Tertiary Setting.

Authors:  Pamela J DiPiro; Katherine M Krajewski; Angela A Giardino; Marta Braschi-Amirfarzan; Nikhil H Ramaiya
Journal:  Korean J Radiol       Date:  2017-01-05       Impact factor: 3.500

5.  Impact of neuroradiologist second opinion on staging and management of head and neck cancer.

Authors:  John T Lysack; Monica Hoy; Mark E Hudon; Steven C Nakoneshny; Shamir P Chandarana; T Wayne Matthews; Joseph C Dort
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-06-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.